Pharmacologic Treatment of Anxiety Disorders in 1989 Versus 1996: Results From the Harvard/Brown Anxiety Disorders Research Program
J Clin Psychiatry 2001;62(3):149-152
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: This article reports on the
pharmacologic treatment of patients diagnosed with generalized
anxiety disorder (GAD) enrolled in a naturalistic long-term study
of anxiety disorders, with enrollment in 1989 through 1991 and
follow-up in 1996.
Method: 711 patients were enrolled in the study
during 1989-1991. At intake, 167 patients met DSM-III-R criteria
for GAD; at 1996 follow-up, 103 patients met these criteria. The
patients were divided into 3 groups by diagnosis: GAD alone (N =
18 at intake, N = 11 at follow-up), GAD comorbid with another
anxiety disorder (N = 84 at intake, N = 52 at follow-up), and GAD
comorbid with Research Diagnostic Criteria-defined major
depressive disorder, with or without another anxiety disorder (N
= 65 at intake, N = 40 at follow-up). The groups were evaluated
at intake and follow-up on whether they received medication and
the types of medication they received.
Results: Nearly one third of patients in the
1989-1991 sample were not receiving any medication for treatment
of their anxiety disorder; in 1996, 27% of patients still were
receiving no medication. There was a decrease in benzodiazepine
treatment and an increase in antidepressant treatment in 1996 for
GAD patients who did not have comorbid depression or another
Conclusion: The finding of one quarter to one
third of patients with GAD receiving no medication is consistent
with previous observations of undertreatment of depression. The
findings on medication type suggest a shift in the type of
medications being prescribed for treatment of GAD from exclusive
benzodiazepine treatment to the combination of benzodiazepine and